CEL-SCI Co. (NYSE:CVM) Shares Sold by Cutter & CO Brokerage Inc.

Cutter & CO Brokerage Inc. cut its position in shares of CEL-SCI Co. (NYSE:CVM) by 17.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 84,711 shares of the company’s stock after selling 18,134 shares during the quarter. Cutter & CO Brokerage Inc.’s holdings in CEL-SCI were worth $230,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in CVM. Black Diamond Financial LLC increased its position in shares of CEL-SCI by 20.5% during the 3rd quarter. Black Diamond Financial LLC now owns 53,000 shares of the company’s stock worth $66,000 after purchasing an additional 9,000 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in shares of CEL-SCI in the 4th quarter valued at approximately $68,000. Finally, Lincoln National Corp lifted its holdings in shares of CEL-SCI by 138.2% in the 3rd quarter. Lincoln National Corp now owns 55,545 shares of the company’s stock worth $69,000 after acquiring an additional 32,225 shares during the last quarter. Hedge funds and other institutional investors own 12.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of CEL-SCI from a “hold” rating to a “sell” rating in a research note on Friday, March 15th.

CEL-SCI Price Performance

CVM traded down $0.02 during trading on Wednesday, hitting $1.45. The company’s stock had a trading volume of 57,193 shares, compared to its average volume of 293,682. The company has a current ratio of 1.26, a quick ratio of 0.78 and a debt-to-equity ratio of 0.75. CEL-SCI Co. has a twelve month low of $1.04 and a twelve month high of $3.23. The firm’s 50 day moving average price is $1.97 and its 200-day moving average price is $2.19.

CEL-SCI (NYSE:CVM) last posted its earnings results on Wednesday, February 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that CEL-SCI Co. will post -0.51 earnings per share for the current year.

CEL-SCI Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.